Keywords
MATS
cross protection
Abstract
A century of traditional vaccinology lost the fight against meningococcus serogroup B (MenB). However, thanks to an innovative genome-based approach, the first broadly effective MenB vaccine, BexseroÂ(GSK Vaccines), was developed and has been licensed for use in various age groups by the EU and other regulatory authorities. Genes encoding for the main meningococcus B antigens were identified and screened in order to achieve a broadly protective vaccine, taking into account the fact that meningococcus B has many different subtypes whose membrane proteins may be different. Since the antigens selected for Bexsero are also harbored by meningococci belonging to other serogroups there may be the potential for Bexsero® to offer a certain level of protection against non-B serogroups. Therefore preliminary studies were carried out to investigate the potential of the vaccine to also provide a degree of cross protection against non-B serogroups. Here we review the potential for Bexsero® to offer a certain level of protection against the diversity of meningococcus type B subtypes and its potential ability to offer some cross protection from non-B serogroups. Lastly, we describe the future perspectives in pentavalent meningococcal vaccine (ABCWY) development which hopefully will result in a vaccine able to help prevent Invasive Meningococcal Diseases (IMD) from the majority of currently circulating meningococcal strains.
References
Hinman AR. Global progress in infectious disease control. Vaccine 1998;16(11-12):1116-1121. Available from: http://hivinsite.ucsf.edu/InSite?page=kb-03-01-08 PubMed PMID: 9682367. doi: 10.1016/S0264-410X(98)80107-2. [Google Scholar]
Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.. N Engl J Med 2009 Jan;360(3):244-256. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0800836?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov PubMed PMID: 19144940. doi: 10.1056/NEJMoa0800836. [Google Scholar]
Black S, Pizza M, Nissum M, et al. Toward a meningitis-free world. Sci Transl Med 2012;4:123. [Google Scholar]
Zollinger WD, Poolman JT, Maiden MCJ. Meningococcal serogroup B vaccines: will they live up to expectations. Expert Review of Vaccines 2011;10(5):559-561. Available from: http://www.tandfonline.com/doi/full/10.1586/erv.11.41 doi: 10.1586/erv.11.41. [Google Scholar]
O'Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program. Drugs 2014;74(1):15-30. Available from: http://europepmc.org/abstract/MED/24338083 PubMed PMID: 24338083. doi: 10.1007/s40265-013-0155-7. [Google Scholar]
Tondella ML, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.. J Clin Microbiol 2000;38(9):3323-3328. Available from: http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=10970378 PubMed PMID: 10970378. [Google Scholar]
Jones D. Reverse vaccinology on the cusp. Nature Reviews Drug Discovery. 2012 AOP. Published online 10 February 2012;Available from(3):175-176. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22322255 PubMed PMID: 22322255. doi: 10.1038/nrd3679. [Google Scholar]
Vernikos G, Medini D. Bexsero® chronicle.. Pathog Glob Health 2014;108(7):305-316. Available from: http://europepmc.org/abstract/MED/25417906 PubMed PMID: 25417906. doi: 10.1179/2047773214Y.0000000162. [Google Scholar]
Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine 2015;33(23):2629-2636. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)00468-5 PubMed PMID: 25882169. doi: 10.1016/j.vaccine.2015.04.015. [Google Scholar]
Ministério da Saúde, Agência Nacional De Vigilância Sanitária Resolução - RE N° 1, de 2 de janeiro de 2015 Suplemento ao No. 2 Brasília - DF, segunda-feira, 5 de janeiro de 2015 http://www.jusbrasil.com.br/ diarios/DOU/ (accessed June 23, 2015)
Bambini S, Piet J, Muzzi A, Keijzers W, Comandi S, Tora, L. De, , et al. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands.. . Available from: http://www.ncbi.nlm.nih.gov/pubmed/23717687 PubMed PMID: 23717687. doi: 10.1371/journal.pone.0065043. [Google Scholar]
Tomei S, Biolchi A, Brunelli B. Potential coverage of Bexsero vaccine on non-B meningococci. Poster presented at 19th IPNC 2014. Asheville, North Carolina, USA: . [Google Scholar]
Goria MCO, Lemos APS, Biolchi A. Impact vaccination with the Novartis meningococcal serogroup B vaccine 4CMenB (BEXSERO®) on non-serogroup B disease burden in Brazil. Poster presented at 32nd ESPID 2014 in. Dublin, Ireland: . [Google Scholar]
Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies.. J Exp Med 1969 Jun;129(6):1307-1326. Available from: http://jem.rupress.org/cgi/pmidlookup?view=long&pmid=4977280 PubMed PMID: 4977280. [Google Scholar]
Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity.. J Exp Med 1969 Jun;129(6):1327-1348. Available from: http://jem.rupress.org/cgi/pmidlookup?view=long&pmid=4977281 PubMed PMID: 4977281. [Google Scholar]
Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969;129:1367. [Google Scholar]
Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state.. J Exp Med 1969 Jun;129(6):1385-1395. Available from: http://jem.rupress.org/cgi/pmidlookup?view=long&pmid=4977284 PubMed PMID: 4977284. [Google Scholar]
Budroni S, Siena E, Dunning Hotopp JC, Seib KL, Serruto D, Nofroni C, et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A 2011 Feb;108(11):4494-4499. Available from: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=21368196 PubMed PMID: 21368196. doi: 10.1073/pnas.1019751108. [Google Scholar]
Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.. Proc Natl Acad Sci U S A 1998 Mar;95(6):3140-3145. Available from: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=9501229 PubMed PMID: 9501229. doi: 10.1073/pnas.95.6.3140. [Google Scholar]
Vogel U, Taha M, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013;13(5):416-425. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1473309913700069 PubMed PMID: 23414709. doi: 10.1016/S1473-3099(13)70006-9. [Google Scholar]
Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010 Oct;107(45):19490-19495. Available from: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=20962280 PubMed PMID: 20962280. doi: 10.1073/pnas.1013758107. [Google Scholar]
Fagnocchi L, Biolchi A, Ferlicca F, et al. Transcriptional regulation of the NadA gene in Neisseria meningitidis impactsthe prediction of coverage of a multicomponent meningococcal serogroup Bvaccine. Infect Immun 2013;81(2):560-569. Available from: http://iai.asm.org/cgi/doi/10.1128/IAI.01085-12 doi: 10.1128/IAI.01085-12. [Google Scholar]
Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006 Jul;103(29):10834-10839. Available from: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=16825336 PubMed PMID: 16825336. doi: 10.1073/pnas.0603940103. [Google Scholar]
Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013;31(43):4968-4974. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264-410X(13)01090-6 PubMed PMID: 23954380. doi: 10.1016/j.vaccine.2013.08.006. [Google Scholar]
Abad R, Biolchi A, Moschioni M, Giuliani MM, Pizza M, Vázquez JA, et al. A Large Portion of Meningococcal Antigen Typing System-Negative Meningococcal Strains from Spain Is Killed by Sera from Adolescents and Infants Immunized with 4CMenB: TABLE 1. Clin. Vaccine Immunol 2015;22(4):357-360. Available from: http://cvi.asm.org/cgi/doi/10.1128/CVI.00669-14 doi: 10.1128/CVI.00669-14. [Google Scholar]
Tozer SJ, Whiley DM, Smith HV, et al. The use of the Meningococcal Antigen Typing System (MATS) to assess Australian epidemiology and meningococcal strain coverage with multicomponent serogroup B vaccine. Poster presented at 27th ICP. 2013.
Hong E, Giuliani MM, Deghmane A, Comanducci M, Brunelli B, Dull P, et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?. Vaccine 2013;31(7):1113-1116. Available from: http://www.diseaseinfosearch.org/result/5121 PubMed PMID: 23261039. doi: 10.1016/j.vaccine.2012.12.022. [Google Scholar]
Joint Committee on Vaccination and Immunization. Minutes of the meeting on 11th/12th February 2014. https://www.gov.uk/government/groups/joint-committee-on-vaccination-andimmunisation#minutes (accessed June 17, 2015).
Pollard AJ, Riordan A, Ramsay M. Group B meningococcal vaccine: recommendations for UK use. The Lancet 2014;383(9923):1103-1104. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673614602269 doi: 10.1016/S0140-6736(14)60226-9. [Google Scholar]
Wals P, Deceuninck G, Lefebvre B, et al. Effectiveness of Serogroup C Meningococcal Conjugate Vaccine A 7-Year Followup in Quebec, Canada. PEDIATR INFECT DIS J 2011;30(7):566-569. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006454-201107000-00007 doi: 10.1097/INF.0b013e31820e8638. [Google Scholar]
Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2006 Dec;31(1):101-107. Available from: http://femsre.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17168998 PubMed PMID: 17168998. doi: 10.1111/j.1574-6976.2006.00053.x. [Google Scholar]
Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.. Vaccine 2015;33(21):2500-2510. Available from: https://www.nlm.nih.gov/medlineplus/meningococcalinfections.html PubMed PMID: 25795256. doi: 10.1016/j.vaccine.2015.03.001. [Google Scholar]
Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Graña MG, Heijnen E, et al. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents. Human Vaccines & Immunotherapeutics 2015;11(6):1507-1517. Available from: http://www.tandfonline.com/doi/full/10.1080/21645515.2015.1029686 doi: 10.1080/21645515.2015.1029686. [Google Scholar]